Cencora company profile
Company profile
Cencora has 47,000 employees and is headquartered in Conshohocken, United States.
Operating a network that moves pharmaceuticals on a scale of $337.4 billion in revenue, Cencora sources and distributes drugs in the United States and abroad. Its U.S. business supplies generic and injectable medicines, over-the-counter products and home healthcare equipment to hospitals, retail and mail-order pharmacies, clinics and long-term care providers, and it also handles plasma, blood products and vaccines. Services range from pharmacy management and staffing to clinical trial support, data analytics for drug makers and supply management software. Products for companion and production animals are also part of the offer. The international segment runs pharmaceutical wholesale and related services, along with specialty transportation and logistics for the biopharmaceutical industry.
In the fiscal year ended September 2026, the company reported revenue of $337.4 billion, up 5.0% from the previous year, and net income of $3.5 billion. It employs 47,000 people and is headquartered in Conshohocken, Pennsylvania.
Company facts
- Sector
- Healthcare
- Industry
- Medical Distribution
- Country
- United States
- Headquarters
- 1 West First Avenue, 19428-1800, Conshohocken
- Employees
- 47,000
- Chief executive
- Robert Mauch
- Founded
- 2001
- Fiscal year
- October - September
- Listing
- COR · NYSE
- Indices
- S&P 500
- Currency
- USD
- ISIN
- US03073E1055
- Website
- cencora.com
Cencora and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| CencoraCOR | United States | $68.11B | 47,000 | 1.4% | 20.0 |
| Cardinal HealthCAH | United States | $64.97B | 58,788 | 1.3% | 36.4 |
| McKessonMCK | United States | $126.04B | 41,600 | 1.6% | 28.2 |
| Henry ScheinHSIC | United States | $9.17B | 25,000 | 5.8% | 22.7 |
| Sigma HealthcareSIG | Australia | $22.55B | — | 9.2% | 48.3 |
| Sinopharm Group Ltd H1099 | Hong Kong SAR China | $6.68B | 94,910 | 3.0% | 6.51 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
